Hyponatremia other diagnostic studies

Hyponatremia Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hyponatremia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiogram or Ultarsound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hyponatremia other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hyponatremia other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hyponatremia other diagnostic studies
CDC on Hyponatremia other diagnostic studies
Hyponatremia other diagnostic studies in the news
Blogs on Hyponatremia other diagnostic studies
Directions to Hospitals Treating hyponatremia
Risk calculators and risk factors for Hyponatremia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Certain newer markers for vasopressin have been identified. Copeptin is currently being studied as a novel biomarker.

Other Diagnostic Studies

• Enzymatic cleavage of vasopressin yields Copeptin and neurophysin. Copeptin is more stable, hence easily measurable. It has found to be increased in patients with hypo or hypervolemic hypernatremia as opposed to SIADH. Two additional markers, apelin and MR-proANP (midregional proatrial natriuretic peptide) are being studied. The true diagnostic potential of these parameters is still being studied.